Journal
SEMINARS IN CANCER BIOLOGY
Volume 73, Issue -, Pages 196-218Publisher
ACADEMIC PRESS LTD- ELSEVIER SCIENCE LTD
DOI: 10.1016/j.semcancer.2020.09.014
Keywords
Silibinin; Flavonolignans; Apoptosis; Cell cycle arrest; Anti-angiogenesis; Anti-metastasis; Clinical studies
Categories
Ask authors/readers for more resources
Silibinin, a naturally derived polyphenol with high antioxidant and anti-tumorigenic properties, exerts its anti-cancer effects through various cellular pathways including apoptosis induction, cell cycle arrest, inhibition of angiogenesis and metastasis. Despite its ability to modulate a wide array of cellular responses, the major obstacle in declaring Silibinin as a translational chemotherapeutic agent lies in its lower bioavailability.
In the last few decades, targeting cancer by the use of dietary phytochemicals has gained enormous attention. The plausible reason and believe or mind set behind this fact is attributed to either lesser or no side effects of natural compounds as compared to the modern chemotherapeutics, or due to their conventional use as dietary components by mankind for thousands of years. Silibinin is a naturally derived polyphenol (a flavonolignans), possess following biochemical features; molecular formula C25H22O10, Molar mass: 482.44 g/mol, Boiling point 793 degrees C, with strikingly high antioxidant and anti-tumorigenic properties. The anti-cancer properties of Silibinin are determined by a variety of cellular pathways which include induction of apoptosis, cell cycle arrest, inhibition of angiogenesis and metastasis. In addition, Silibinin controls modulation of the expression of aberrant miRNAs, inflammatory response, and synergism with existing anti-cancer drugs. Therefore, modulation of a vast array of cellular responses and homeostatic aspects makes Silibinin an attractive chemotherapeutic agent. However, like other polyphenols, the major hurdle to declare Silibinin a translational chemotherapeutic agent, is its lesser bioavailability. After summarizing the chemistry and metabolic aspects of Silibinin, this extensive review focuses on functional aspects governed by Silibinin in chemoprevention with an ultimate goal of summarizing the evidence supporting the chemopreventive potential of Silibinin and clinical trials that are currently ongoing, at a single platform.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available